Advanz Pharma
Nordic Capital
Nordic Capital
40900000
2021
20210729
competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
The Competition and Markets Authority (CMA) found that from 2009 until 2017 the pharmaceutical company Advanz charged excessive and unfair prices for supplying liothyronine tablets which are used to treat thyroid hormone deficiency. The agency also fined two private equity firms, HGCapital and Cinven, that previously owned parts of the business.
agency action
UK-CMA
Competition and Markets Authority
Sweden
privately held
private equity (including portfolio companies)
private equity (including portfolio companies)
https://www.gov.uk/government/news/cma-fines-pharma-firm-over-pricing-of-crucial-thyroid-drug
UK21-158
Focus Pharmaceuticals Limited and Focus Pharma Holdings Limited
Nordic Capital
Nordic Capital
549343
2022
20220203
competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
Alliance Pharmaceuticals Limited and Alliance Pharma plc, Focus Pharmaceuticals Limited, Focus Pharma Holdings Limited, Mercury Pharma Group Limited, Concordia Investment Holdings (UK) Limited, Concordia Investments (Jersey) Limited and Advanz Pharma Corp. Limited, Cinven Capital Management (V) General Partner Limited, Cinven (Luxco 1) S.A .r.l and Cinven Partners LLP, Lexon (UK) Limited and Lexon UK Holdings Limited, Medreich plc, Medreich Ltd, Meiji Seika Pharma Co. Ltd and Meiji Holdings Co. Ltd. were fined by the CMA following an investigation finding that the companies engaged in anti-competitive behaviour to increase the price of the drug prochlorperazine. Medreich's fine had a 40% leniency reduction for cooperating with the investigation.
agency action
UK-CMA
Competition and Markets Authority
Sweden
privately held
private equity (including portfolio companies)
private equity (including portfolio companies)
https://www.gov.uk/government/news/cma-fines-firms-over-35m-for-illegal-arrangement-for-nhs-drug
UK21-68593
Focus Pharmaceuticals Ltd. and Focus Pharma Holdings Ltd. and Mercury Pharma Group Ltd.
Nordic Capital
Nordic Capital
921357
2022
20220203
competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
Alliance Pharmaceuticals Limited and Alliance Pharma plc, Focus Pharmaceuticals Limited, Focus Pharma Holdings Limited, Mercury Pharma Group Limited, Concordia Investment Holdings (UK) Limited, Concordia Investments (Jersey) Limited and Advanz Pharma Corp. Limited, Cinven Capital Management (V) General Partner Limited, Cinven (Luxco 1) S.A .r.l and Cinven Partners LLP, Lexon (UK) Limited and Lexon UK Holdings Limited, Medreich plc, Medreich Ltd, Meiji Seika Pharma Co. Ltd and Meiji Holdings Co. Ltd. were fined by the CMA following an investigation finding that the companies engaged in anti-competitive behaviour to increase the price of the drug prochlorperazine. Medreich's fine had a 40% leniency reduction for cooperating with the investigation.
agency action
UK-CMA
Competition and Markets Authority
Sweden
privately held
private equity (including portfolio companies)
private equity (including portfolio companies)
https://www.gov.uk/government/news/cma-fines-firms-over-35m-for-illegal-arrangement-for-nhs-drug
UK21-68595
Focus Pharmaceuticals Limited and Mercury Pharma Group Ltd. and Cinven Partners LLP et al.
Nordic Capital
Nordic Capital
1843380
2022
20220203
competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
Alliance Pharmaceuticals Limited and Alliance Pharma plc, Focus Pharmaceuticals Limited, Focus Pharma Holdings Limited, Mercury Pharma Group Limited, Concordia Investment Holdings (UK) Limited, Concordia Investments (Jersey) Limited and Advanz Pharma Corp. Limited, Cinven Capital Management (V) General Partner Limited, Cinven (Luxco 1) S.A .r.l and Cinven Partners LLP, Lexon (UK) Limited and Lexon UK Holdings Limited, Medreich plc, Medreich Ltd, Meiji Seika Pharma Co. Ltd and Meiji Holdings Co. Ltd. were fined by the CMA following an investigation finding that the companies engaged in anti-competitive behaviour to increase the price of the drug prochlorperazine. Medreich's fine had a 40% leniency reduction for cooperating with the investigation.
agency action
UK-CMA
Competition and Markets Authority
Sweden
privately held
private equity (including portfolio companies)
private equity (including portfolio companies)
https://www.gov.uk/government/news/cma-fines-firms-over-35m-for-illegal-arrangement-for-nhs-drug
UK21-68597
Focus Pharmaceuticals Limited and Mercury Pharma Group Ltd. and Concordia Investments (Jersey) Ltd. and Advanz Pharma Corp. Ltd. et al.
Nordic Capital
Nordic Capital
7288853
2022
20220203
competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
Alliance Pharmaceuticals Limited and Alliance Pharma plc, Focus Pharmaceuticals Limited, Focus Pharma Holdings Limited, Mercury Pharma Group Limited, Concordia Investment Holdings (UK) Limited, Concordia Investments (Jersey) Limited and Advanz Pharma Corp. Limited, Cinven Capital Management (V) General Partner Limited, Cinven (Luxco 1) S.A .r.l and Cinven Partners LLP, Lexon (UK) Limited and Lexon UK Holdings Limited, Medreich plc, Medreich Ltd, Meiji Seika Pharma Co. Ltd and Meiji Holdings Co. Ltd. were fined by the CMA following an investigation finding that the companies engaged in anti-competitive behaviour to increase the price of the drug prochlorperazine. Medreich's fine had a 40% leniency reduction for cooperating with the investigation.
agency action
UK-CMA
Competition and Markets Authority
Sweden
privately held
private equity (including portfolio companies)
private equity (including portfolio companies)
https://www.gov.uk/government/news/cma-fines-firms-over-35m-for-illegal-arrangement-for-nhs-drug
UK21-68601
5